Search company, investor...


Founded Year



Series A | Alive

Total Raised


Last Raised

$35M | 2 yrs ago

About Inipharm

Inipharm advances a therapeutic pipeline that addresses severe liver diseases with a focus on the HSD17B13 gene.

Headquarters Location


United States

Missing: Inipharm's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: Inipharm's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing Inipharm

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Inipharm is included in 1 Expert Collection, including Biopharma Tech.


Biopharma Tech

5,241 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Latest Inipharm News

Possible NAFLD name change must benefit both patients, field of hepatology

Feb 20, 2023

Source: Healio interviews Disclosures: Loomba reports financial relationships with 89bio, Aardvark Therapeutics, Altimmune, Alnylam/Regeneron, Amgen, Arrowhead Pharmaceuticals, AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, CohBar, Eli Lilly, Galectin Therapeutics, Galmed, Gilead Sciences, Glympse Bio, High-Tide Therapeutics, Inipharm, Intercept, Inventiva, Ionis, Janssen, Madrigal, Merck, Metacrine, NGM Bio, Novartis, Novo Nordisk, Pfizer, Sagimet, Sonic Incytes, Terns Pharmaceuticals, Theratechnologies and Viking Therapeutics. He also co-founded LipoNexus Inc. ADD TOPIC TO EMAIL ALERTS Receive an email when new articles are posted on Please provide your email address to receive an email when new articles are posted on . Please try again later. If you continue to have this issue please contact . Back to Healio Regarding the nonalcoholic fatty liver disease nomenclature debate, I am pretty neutral to what the new name should be, and I want to be sensitive to all parties involved. There are some people who are passionate about changing the name and others who feel it should not change. Whatever we decide to do, it must be helpful to our patients and to the hepatology field. Currently, the No. 1 need our patients have is treatment for nonalcoholic steatohepatitis-related fibrosis. We have FDA and European Medicines Agency guidance that is linked to a particular natural history of disease and diagnosis of NASH stage 2 fibrosis or higher. To me, we should do everything to protect that integrity so we can continue to develop drugs for a particular indication. If it really affects that particular entity who needs to be treated — a patient with NASH stage 2 fibrosis or higher — that will have a major negative impact on the field. Rohit Loomba, MD, MHSc Anything not done with caution can have an impact on the field. It is important to understand all parties, take their views into account and come up with a consensus. That is what people are trying to do in AASLD, EASL and all the other societies, and also stakeholders, patients and their voices. I hope that this process satisfies all parties involved when completed. There have been considerations on removing “fatty” from NAFLD and changing the term to “steatotic liver disease.” Additionally, there are discussions regarding metabolic dysfunction and associated fatty liver disease and whether we should include those who have alcohol-associated fatty liver into the broader terminology. There are many things that are currently happening. We wish that there were new pathogenetic mechanisms available to really risk-stratify patients based upon that and then change the nomenclature. Once we really understand the disease states better in the next 5 or 6 years, we may actually have further sub-classifications. We should develop a change in name, though it should not change the history of those who need to be treated [or derail] the drug development or the biomarker development within the broader field of NASH. For more information: Rohit Loomba, MD, MHSc, is professor of medicine, director of hepatology and the NAFLD Research Center, and vice chief of gastroenterology at the University of California, San Diego. Read more about

Inipharm Frequently Asked Questions (FAQ)

  • When was Inipharm founded?

    Inipharm was founded in 2018.

  • What is Inipharm's latest funding round?

    Inipharm's latest funding round is Series A.

  • How much did Inipharm raise?

    Inipharm raised a total of $63.5M.

  • Who are the investors of Inipharm?

    Investors of Inipharm include 5AM Ventures, Wu Capital and Jubilant Life Sciences.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.